Sign in

NCT04340024Recruiting

Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients

Source: ClinicalTrials.gov · Last updated 11 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study. Blood and/or matched tumour-normal tissue pairs will be collected. Blood and/or tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.

Status (registry)
Recruiting
Study type
Observational
Enrollment
5000 (estimated)
First submitted
26 Mar 2020
Start date
30 Sept 2015
Primary completion date
31 Dec 2026
Lead sponsor
National Cancer Centre, Singapore
NCT number
NCT04340024

What you commit to

  • Study type: Observational
  • Planned participants: 5000
  • From 30 Sept 2015 to the primary completion date, 31 Dec 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age

  • Age of patient must be between 21 (inclusive) and 99 (exclusive)

Who the study is looking for

  • Patients with severe side effects from radiotherapy
  • Patients with a type of cancer that is associated with sensitivity to radiotherapy

Age in the registry: 21 years to 99 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
National Cancer Center Singapore
Coordinator of this site? Confirm its status
SingaporeSingaporeRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.